JP2023546743A5 - - Google Patents
Info
- Publication number
- JP2023546743A5 JP2023546743A5 JP2023548995A JP2023548995A JP2023546743A5 JP 2023546743 A5 JP2023546743 A5 JP 2023546743A5 JP 2023548995 A JP2023548995 A JP 2023548995A JP 2023548995 A JP2023548995 A JP 2023548995A JP 2023546743 A5 JP2023546743 A5 JP 2023546743A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- amino acid
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011152518.9 | 2020-10-23 | ||
| CN202011152518 | 2020-10-23 | ||
| PCT/CN2021/125564 WO2022083723A1 (zh) | 2020-10-23 | 2021-10-22 | 抗cd73的抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546743A JP2023546743A (ja) | 2023-11-07 |
| JP2023546743A5 true JP2023546743A5 (enExample) | 2025-05-20 |
Family
ID=81291626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548995A Pending JP2023546743A (ja) | 2020-10-23 | 2021-10-22 | 抗ｃｄ７３抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240018254A1 (enExample) |
| EP (1) | EP4234579A4 (enExample) |
| JP (1) | JP2023546743A (enExample) |
| KR (1) | KR20230125774A (enExample) |
| CN (2) | CN114478768B (enExample) |
| AU (1) | AU2021363350A1 (enExample) |
| CA (1) | CA3196299A1 (enExample) |
| IL (1) | IL302182A (enExample) |
| MX (1) | MX2023004713A (enExample) |
| WO (1) | WO2022083723A1 (enExample) |
| ZA (1) | ZA202304591B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| WO2023236971A1 (zh) * | 2022-06-08 | 2023-12-14 | 上海华奥泰生物药业股份有限公司 | Cd73抗体鸡尾酒疗法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117567613A (zh) * | 2022-12-13 | 2024-02-20 | 华润生物医药有限公司 | 抗cd73抗体及其用途 |
| CN117567615A (zh) * | 2022-12-13 | 2024-02-20 | 华润生物医药有限公司 | 抗cd73抗体及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2016055609A1 (en) * | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| RS62003B2 (sr) * | 2014-11-10 | 2025-01-31 | Medimmune Ltd | Vezujući molekuli specifični za cd73 i njihove upotrebe |
| EP3789403A1 (en) * | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| JP6805142B2 (ja) * | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| CN104558137A (zh) * | 2015-01-15 | 2015-04-29 | 浙江欧诗漫生物股份有限公司 | 一种珍珠蛋白的制备方法及该方法制备得到的水溶性珍珠蛋白和酸溶性珍珠蛋白 |
| EP3259288B1 (en) * | 2015-02-20 | 2026-07-22 | Innate Pharma | Cd73 blockade |
| WO2017064043A1 (en) * | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| CA3007646A1 (en) * | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CA3046432A1 (en) * | 2016-12-13 | 2018-06-21 | Astellas Pharma Inc. | Anti-human cd73 antibody |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| MX2019015885A (es) * | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| AU2019231172B2 (en) * | 2018-03-09 | 2023-08-24 | Phanes Therapeutics, Inc. | Anti-CD73 antibodies and uses thereof |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| WO2021213466A1 (zh) * | 2020-04-22 | 2021-10-28 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| BR112022021426A2 (pt) * | 2020-04-22 | 2022-12-13 | Akeso Biopharma Inc | Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73 |
-
2021
- 2021-10-22 JP JP2023548995A patent/JP2023546743A/ja active Pending
- 2021-10-22 WO PCT/CN2021/125564 patent/WO2022083723A1/zh not_active Ceased
- 2021-10-22 CN CN202111237197.7A patent/CN114478768B/zh active Active
- 2021-10-22 IL IL302182A patent/IL302182A/en unknown
- 2021-10-22 AU AU2021363350A patent/AU2021363350A1/en active Pending
- 2021-10-22 KR KR1020237017266A patent/KR20230125774A/ko active Pending
- 2021-10-22 CN CN202510730743.2A patent/CN120590533A/zh active Pending
- 2021-10-22 US US18/250,010 patent/US20240018254A1/en active Pending
- 2021-10-22 EP EP21882137.9A patent/EP4234579A4/en active Pending
- 2021-10-22 MX MX2023004713A patent/MX2023004713A/es unknown
- 2021-10-22 CA CA3196299A patent/CA3196299A1/en active Pending
-
2023
- 2023-04-20 ZA ZA2023/04591A patent/ZA202304591B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| CA2560305C (en) | Human anti-epidermal growth factor receptor antibody | |
| JP2021514664A5 (enExample) | ||
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| JP2024544520A5 (enExample) | ||
| BR112021003559A2 (pt) | anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica | |
| CN116731180A (zh) | 抗ror1抗体及其制备和使用方法 | |
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2021528047A5 (enExample) | ||
| WO2022111616A1 (zh) | 抗cldn18.2抗体、药物偶联物及其制备方法和用途 | |
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| US11965037B2 (en) | Anti-HER3 humanized monoclonal antibody | |
| WO2015076425A1 (ja) | 新規モノクローナル抗体 | |
| CN115785268B (zh) | 抗cd47抗体及其用途 | |
| JP2025114620A5 (enExample) | ||
| WO2019078698A2 (ko) | 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물 | |
| IL296572A (en) | Antibodies against muc1-sea | |
| TW202317630A (zh) | 抗gfral抗體及其應用 | |
| EP4640707A1 (en) | Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof | |
| JP2021523906A5 (enExample) | ||
| CN118047871A (zh) | 一种靶向FRα的抗体或其抗原结合片段及其应用 | |
| TW202108631A (zh) | 一種抗ｃｄ４７抗原結合蛋白及其應用 | |
| EP3436483A1 (en) | Erbb2-targeting antibody | |
| JP2024522075A5 (enExample) |